See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Patenting drug repurposing programs is a significant part of the NLO's pharma team of patent attorneys. Despite successes, it is common that researchers are not fully aware of the patenting possibilities, and even better, opportunities it can offer for contributing to the success: raising sufficient financial resources for amongst others clinical trials and the registration process, and ultimately reaching the goal of providing patients the new repurposed drug for solving their unmet medical needs. Therefore, the conference provides a perfect platform for sharing our insights and knowledge on drug repurposing patenting, and for fruitful discussions on the what, how and when. Do's and certainly also Don'ts will be expressed in order to optimize the odds for successful patenting and for avoiding disappointments, for example due to timely or the opposite, too late filing of patent applications. It is through meetings like this that great ideas can growth and gain momentum. We feel that contributing to the drug repurposing community is beneficial for improving the chance for success.